All companies
Visit website
TrippBio
OperatingTrippBio, Inc
Healthcare · Founded 2020
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Post-money valuation ⓘ
$24.8M
As of Feb 2025 · from TrippBio Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$184,644
Across 2 rounds since 2020
Latest share price
$0.42
TrippBio Common Stock 2 offering price
Financials
FY2018–FY2023 · from SEC filings · hover any figure for its source$0
2018
$0
2019
$0
−$866K
2020
$0
−$1.6M
2022
$0
−$1.4M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2022
FY2023
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
Net income
$0
$0
-$866,473
-$1,587,708
-$1,377,605
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$0
$49,567
$11,613
$337
Accounts receivable
$0
$0
$0
$0
$0
Total assets
$0
$0
$49,577
$11,613
$337
Short-term debt
$0
$0
$507,034
$293,708
$376,100
Long-term debt
$0
$0
$0
$1,898,824
$2,518,962
Total liabilities
$0
$0
$507,034
$2,192,532
$2,895,062
Other
Headcount
—
18
0
—
9
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$5.4M
post-money
$24.8M
post-money
TrippBio, Inc. Stock 1
TrippBio Common Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $618KPost-money $24.8M
Raised $184.6K / $1.1MPost-money $5.4M
Reg CF annual-report compliance
Possibly delinquent
Filed 2 of 6 annual reports (FY2020–FY2025)
Missing: 2021, 2022, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGARSource: ManualCIK 0001817701Share price $0.42
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.